“Psychosocial interventions in prostate cancer offer limited benefits”

The heading above is the title of a Reuters-generated article on the Medcape Oncology web site. The article is based on a new review article just published in BJU International. … READ MORE …

Side effects of salvage radiation — difficult to draw conclusions based on database analyses

Two analyses of Italian and US databases have investigated whether delaying initiation of radiation therapy could diminish the side effects of radiation after prostatectomy. The conventional wisdom is that waiting longer allows the newly cut tissues more time to heal completely before the onslaught of radiation. … READ MORE …

Low detectable PSA after prostatectomy – watch or treat?

In a previous article, we looked at evidence that a low detectable level of PSA predicts eventual biochemical recurrence (a confirmed PSA greater than 0.2 ng/ml) when there is aggressive pathology. … READ MORE …

When should the patient and doctor consider salvage radiation therapy?

Patients and their doctors often have to make a critical decision soon after surgery – at what point after surgery, if at all, should salvage radiation therapy be started? … READ MORE …

Re-thinking the application of hormone therapy

There has long been discussion about the appropriate and inappropriate uses of androgen deprivation therapy (ADT) in the management of progressive prostate cancer. The “New” Prostate Cancer InfoLink has regularly commented on the inherent dangers of using ADT to “manage PSA levels” as opposed to managing a patient’s actual clinical condition. … READ MORE …

Timing of salvage hormone therapy when radiotherapy has failed

The question of when one should initiate hormone therapy in a man who has a rising PSA after radiation therapy has long been a topic of controversy. And a reanalysis of data from RTOG 85-31 has not helped to give us a definitive answer. … READ MORE …

Hormone therapy effective in man with PSA > 21,000, but …

An article in just published in Onkologie reports the diagnosis and (short-term) treatment of widely disseminated, metastatic prostate cancer in a 64-year-old Croatian man with a PSA of > 21,000 ng/ml. … READ MORE …